Shandong Lukang Pharmaceutical Co Ltd (600789) - Net Assets

Latest as of March 2026: CN¥5.31 Billion CNY ≈ $777.43 Million USD

Based on the latest financial reports, Shandong Lukang Pharmaceutical Co Ltd (600789) has net assets worth CN¥5.31 Billion CNY (≈ $777.43 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥9.88 Billion ≈ $1.45 Billion USD) and total liabilities (CN¥4.57 Billion ≈ $668.77 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 600789 asset base for the complete picture of this company's asset base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥5.31 Billion
% of Total Assets	53.76%
Annual Growth Rate	11.65%
5-Year Change	54.64%
10-Year Change	165.22%
Growth Volatility	25.06

Shandong Lukang Pharmaceutical Co Ltd - Net Assets Trend (1993–2025)

This chart illustrates how Shandong Lukang Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Check Shandong Lukang Pharmaceutical Co Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Annual Net Assets for Shandong Lukang Pharmaceutical Co Ltd (1993–2025)

The table below shows the annual net assets of Shandong Lukang Pharmaceutical Co Ltd from 1993 to 2025. For live valuation and market cap data, see Shandong Lukang Pharmaceutical Co Ltd stock valuation.

Year	Net Assets	Change
2025-12-31	CN¥5.26 Billion ≈ $769.21 Million	+29.42%
2024-12-31	CN¥4.06 Billion ≈ $594.34 Million	+8.56%
2023-12-31	CN¥3.74 Billion ≈ $547.48 Million	+6.68%
2022-12-31	CN¥3.51 Billion ≈ $513.21 Million	+3.18%
2021-12-31	CN¥3.40 Billion ≈ $497.41 Million	+1.19%
2020-12-31	CN¥3.36 Billion ≈ $491.57 Million	+5.92%
2019-12-31	CN¥3.17 Billion ≈ $464.11 Million	+3.26%
2018-12-31	CN¥3.07 Billion ≈ $449.48 Million	+46.35%
2017-12-31	CN¥2.10 Billion ≈ $307.12 Million	+5.89%
2016-12-31	CN¥1.98 Billion ≈ $290.03 Million	+4.03%
2015-12-31	CN¥1.91 Billion ≈ $278.80 Million	+26.66%
2014-12-31	CN¥1.50 Billion ≈ $220.11 Million	-7.99%
2013-12-31	CN¥1.63 Billion ≈ $239.22 Million	+1.73%
2012-12-31	CN¥1.61 Billion ≈ $235.15 Million	-5.11%
2011-12-31	CN¥1.69 Billion ≈ $247.82 Million	+1.01%
2010-12-31	CN¥1.68 Billion ≈ $245.35 Million	+8.31%
2009-12-31	CN¥1.55 Billion ≈ $226.53 Million	+3.14%
2008-12-31	CN¥1.50 Billion ≈ $219.63 Million	+2.78%
2007-12-31	CN¥1.46 Billion ≈ $213.69 Million	+2.69%
2006-12-31	CN¥1.42 Billion ≈ $208.09 Million	-5.10%
2005-12-31	CN¥1.50 Billion ≈ $219.27 Million	+0.21%
2004-12-31	CN¥1.50 Billion ≈ $218.82 Million	-7.40%
2003-12-31	CN¥1.61 Billion ≈ $236.31 Million	+28.18%
2002-12-31	CN¥1.26 Billion ≈ $184.36 Million	+8.45%
2001-12-31	CN¥1.16 Billion ≈ $170.00 Million	+2.77%
2000-12-31	CN¥1.13 Billion ≈ $165.42 Million	+2.78%
1999-12-31	CN¥1.10 Billion ≈ $160.95 Million	-1.82%
1998-12-31	CN¥1.12 Billion ≈ $163.93 Million	+26.58%
1997-12-31	CN¥885.05 Million ≈ $129.51 Million	+120.24%
1996-12-31	CN¥401.85 Million ≈ $58.80 Million	+28.40%
1995-12-31	CN¥312.96 Million ≈ $45.80 Million	+68.13%
1994-12-31	CN¥186.15 Million ≈ $27.24 Million	+20.24%
1993-12-31	CN¥154.81 Million ≈ $22.65 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Shandong Lukang Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 206617.4% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥1.14 Billion	22.33%
Other Components	CN¥3.97 Billion	77.67%
Total Equity	CN¥5.11 Billion	100.00%

Shandong Lukang Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Shandong Lukang Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund NYSE:PTA	$1.07 Billion
Changzhou NRB Corp SHE:002708	$1.07 Billion
Jingjin Environmental Protection Co Ltd SHG:603279	$1.07 Billion
Puuilo Oyj HE:PUUILO	$1.07 Billion
SUPERLOOP LTD F:9SL	$1.07 Billion
Beijing Haitian Ruisheng Science Technology Ltd SHG:688787	$1.07 Billion
SKAN Group AG SW:SKAN	$1.07 Billion
Baota Industry Co Ltd SHE:000595	$1.07 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Shandong Lukang Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 3,918,185,000 to 5,114,660,477, a change of 1,196,475,477 (30.5%).
Net income of 112,304,824 contributed positively to equity growth.
Dividend payments of 166,297,756 reduced retained earnings.
Other factors increased equity by 1,250,468,409.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥112.30 Million	+2.2%
Dividends Paid	CN¥166.30 Million	-3.25%
Other Changes	CN¥1.25 Billion	+24.45%
Total Change	CN¥-	30.54%

Book Value vs Market Value Analysis

This analysis compares Shandong Lukang Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.43x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 38.17x to 1.43x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1993-12-31	CN¥0.18	CN¥7.00	x
1994-12-31	CN¥0.22	CN¥7.00	x
1995-12-31	CN¥0.26	CN¥7.00	x
1996-12-31	CN¥0.48	CN¥7.00	x
1997-12-31	CN¥1.05	CN¥7.00	x
1998-12-31	CN¥1.33	CN¥7.00	x
1999-12-31	CN¥1.30	CN¥7.00	x
2000-12-31	CN¥1.34	CN¥7.00	x
2001-12-31	CN¥1.38	CN¥7.00	x
2002-12-31	CN¥2.35	CN¥7.00	x
2003-12-31	CN¥3.02	CN¥7.00	x
2004-12-31	CN¥2.80	CN¥7.00	x
2005-12-31	CN¥2.80	CN¥7.00	x
2006-12-31	CN¥2.49	CN¥7.00	x
2007-12-31	CN¥2.08	CN¥7.00	x
2008-12-31	CN¥1.94	CN¥7.00	x
2009-12-31	CN¥1.87	CN¥7.00	x
2010-12-31	CN¥2.15	CN¥7.00	x
2011-12-31	CN¥2.56	CN¥7.00	x
2012-12-31	CN¥2.01	CN¥7.00	x
2013-12-31	CN¥2.16	CN¥7.00	x
2014-12-31	CN¥1.90	CN¥7.00	x
2015-12-31	CN¥1.76	CN¥7.00	x
2016-12-31	CN¥2.45	CN¥7.00	x
2017-12-31	CN¥2.64	CN¥7.00	x
2018-12-31	CN¥3.45	CN¥7.00	x
2019-12-31	CN¥3.43	CN¥7.00	x
2020-12-31	CN¥3.53	CN¥7.00	x
2021-12-31	CN¥3.70	CN¥7.00	x
2022-12-31	CN¥3.65	CN¥7.00	x
2023-12-31	CN¥4.03	CN¥7.00	x
2024-12-31	CN¥4.37	CN¥7.00	x
2025-12-31	CN¥4.89	CN¥7.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Shandong Lukang Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 2.20%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 1.95%
• Asset Turnover: 0.57x
• Equity Multiplier: 1.96x
Recent ROE (2.20%) is below the historical average (5.55%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1993	20.86%	8.14%	0.98x	2.62x	CN¥16.81 Million
1994	32.89%	14.09%	0.97x	2.42x	CN¥42.60 Million
1995	29.68%	13.53%	0.77x	2.84x	CN¥43.74 Million
1996	21.33%	14.35%	0.76x	1.96x	CN¥45.53 Million
1997	10.68%	13.69%	0.52x	1.50x	CN¥6.06 Million
1998	5.25%	10.45%	0.36x	1.39x	CN¥-53.16 Million
1999	4.21%	7.81%	0.33x	1.63x	CN¥-63.72 Million
2000	5.03%	8.10%	0.31x	2.01x	CN¥-56.24 Million
2001	6.07%	9.14%	0.32x	2.05x	CN¥-45.71 Million
2002	7.66%	9.28%	0.44x	1.87x	CN¥-29.48 Million
2003	3.35%	5.56%	0.36x	1.67x	CN¥-107.37 Million
2004	-6.18%	-8.99%	0.38x	1.80x	CN¥-241.89 Million
2005	0.33%	0.43%	0.45x	1.73x	CN¥-144.87 Million
2006	-6.79%	-8.67%	0.46x	1.71x	CN¥-238.67 Million
2007	1.78%	1.85%	0.56x	1.72x	CN¥-119.98 Million
2008	2.38%	2.03%	0.69x	1.69x	CN¥-112.82 Million
2009	2.47%	1.93%	0.78x	1.63x	CN¥-114.84 Million
2010	7.86%	5.90%	0.73x	1.83x	CN¥-35.25 Million
2011	0.90%	0.64%	0.67x	2.09x	CN¥-151.26 Million
2012	-8.81%	-5.72%	0.59x	2.62x	CN¥-285.70 Million
2013	0.71%	0.49%	0.54x	2.67x	CN¥-141.89 Million
2014	-8.89%	-5.42%	0.57x	2.90x	CN¥-266.10 Million
2015	0.44%	0.33%	0.60x	2.22x	CN¥-173.12 Million
2016	1.57%	1.16%	0.60x	2.25x	CN¥-156.43 Million
2017	5.83%	4.39%	0.50x	2.66x	CN¥-81.55 Million
2018	5.51%	4.85%	0.51x	2.24x	CN¥-131.33 Million
2019	4.01%	3.25%	0.53x	2.35x	CN¥-180.86 Million
2020	7.09%	5.42%	0.58x	2.26x	CN¥-93.52 Million
2021	2.74%	1.81%	0.63x	2.39x	CN¥-236.30 Million
2022	4.11%	2.46%	0.64x	2.60x	CN¥-197.67 Million
2023	6.82%	4.00%	0.70x	2.44x	CN¥-115.00 Million
2024	10.07%	6.33%	0.69x	2.32x	CN¥2.80 Million
2025	2.20%	1.95%	0.57x	1.96x	CN¥-399.16 Million

Industry Comparison

This section compares Shandong Lukang Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $5,862,898,604
Average return on equity (ROE) among peers: 12.33%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Shandong Lukang Pharmaceutical Co Ltd (600789)	CN¥5.31 Billion	20.86%	0.86x	$1.07 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$2.14 Billion	22.15%	4.96x	$631.43 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$536.15 Million	4.62%	0.32x	$369.91 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$2.82 Billion	20.67%	0.28x	$4.48 Billion
Livzon Pharmaceutical Group Inc (000513)	$11.23 Billion	39.42%	0.42x	$2.68 Billion
Wedge Industrial Co Ltd (000534)	$524.15 Million	5.63%	0.06x	$2.42 Billion
Yunnan Baiyao Group Co Ltd (000538)	$39.91 Billion	10.26%	0.35x	$12.87 Billion
Hainan Haiyao Co Ltd (000566)	$265.38 Million	9.41%	0.86x	$1.22 Billion
Tus Pharmaceutical Group Co Ltd (000590)	$240.92 Million	10.02%	0.55x	$297.86 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$873.28 Million	1.11%	2.07x	$956.43 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$89.69 Million	0.00%	1.30x	$3.28 Billion

About Shandong Lukang Pharmaceutical Co Ltd

SHG:600789 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.07 Billion

CN¥7.32 Billion CNY

Market Cap Rank

#8727 Global

#2144 in China

Share Price

CN¥7.00

Change (1 day)

+0.57%

52-Week Range

CN¥6.81 - CN¥10.91

All Time High

CN¥16.22